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Abstract
Background: Current treatments of panic disorder (PD) are limited by adverse effects, poor efficacy, and need for
chronic administration. The established safety profile of subanesthetic concentrations of xenon gas, which is known
to act as a glutamate subtype NMDA receptor antagonist, coupled with preclinical studies demonstrating its effects in
other anxiety related conditions, prompted us to evaluate its feasibility and efficacy in treatment of patients with PD.
Methods: An open-label clinical trial of xenon–oxygen mixture was conducted in 81 patients with PD; group 1 consisting of patients only with PD (N = 42); and group 2 patients with PD and other comorbidities (N = 39).
Results: Based on the analysis of the results of a number of psychometric scales used in this study (SAS, HADS,
CGI), several conclusions can be made: (1) xenon is a potentially effective modality in acute treatment of PD; (2) an
anti-panic effect of xenon administration persists for at least 6 months after the completion of the active phase of
treatment; (3) xenon inhalation is well tolerated, with the drop-out rates being much lower than that of conventional
pharmacotherapy (5.8% vs. 15%); (4) the severity of depressive disorders that frequently accompany PD can be significantly reduced with the use of xenon; (5) xenon may be considered as an alternative to benzodiazepines in conjunction with cognitive-behavioral therapy as a safe modality in treatment of anxiety disorder.
Conclusions: These data support the need for randomized double-blind clinical trials to further study xenon-based
interventions.
Trial registration This clinical trial was retrospectively registered on April 14th, 2017 as ISRCTN15184285 in the ISRCTN
database.
Keywords: Panic disorder, Xenon therapy, Inhalation of xenon, Comorbidity
Background
One of the most common anxiety disorders is panic disorder (PD), with a 12 month prevalence in the US and
in Europe estimated at 1.8 and 2.7% of the population,
respectively [1, 2]; the main clinical feature of which is an
unexpected panic attack (PA) that arises in the absence
of any situational or emotional triggers, reaching its peak
intensity within minutes, that is manifested by intense
physical and cognitive symptoms, such as fear of recurrence, general health concerns, and behavioral changes
[3, 4]. In addition to spontaneous PA, its other forms
include situationally predisposed PA, “symptomatically
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mild” (“minor”) PA [5], in which less than 4 out of 13
symptoms listed in the DSM-IV are present, and “nocturnal” panic attacks that occur during phase 2 of the sleep
cycle [6].
Panic disorder in its “pure” form is found only in 24.6%
of cases, in 36.7% of cases it is accompanied by a comorbid disorder, in 13.3% —by 2, and in 23.5%—by 3 or more
mental disorders, mainly anxiety and diseases of depressive spectrum [7]. Lecrubier et al. had shown that individuals with isolated panic attacks are more prone to the
development of depression (45.6%) than to development
of a panic disorder [8].
To date, the greatest clinical evidence of efficacy in
the treatment of PD has been demonstrated with the
use of selective serotonin reuptake inhibitors (SSRIs),
serotonin–norepinephrine reuptake inhibitors (SNRIs)
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(drugs of first choice) and benzodiazepine tranquilizers (drugs of second choice) [9]. Disadvantages of SSRIs/
SNRIs therapy include delayed onset of therapeutic
effect (2–6 weeks), and side effects at the start of therapy,
which can limit its use in the treatment of PD, especially
given the importance of achievement of rapid anxiolytic
effect [10, 11]. While benzodiazepines have immediate
onset of action, their side effect profile is significant and
includes excessive sedation, slow reaction time, dizziness,
and possible paradoxical reactions such as anxiety [12].
In addition, knowledge of benzodiazepines’ high risk of
dependence [13, 14], often forces patients with PD leading an active lifestyle, to seek other, alternative methods
of treatment. These side effects in themselves can exacerbate PD and become the triggers of panic attacks. Historically, 18% of patients receiving SSRIs and 15% of patients
receiving benzodiazepines drop-out from clinical studies
[8]. To our knowledge, the contemporary scientific literature contains practically no data on the treatment of
refractory PD, where both first- and second-line treatment options are ineffective. Additionally, there are frequent clinical scenarios where PD exists concomitantly
with other psychiatric comorbidities or where panic
attacks don’t reach the diagnostic threshold of a panic
disorder, but nevertheless have a significant impact on
the course of the underlying disease and impair social
functioning. Thus, the search for an alternative treatment
modality with non-habit forming anxiolytic effect and
minimal side effects aimed at rapid relief of panic attacks
represents an urgent unmet need in the treatment of PD.
Anxiety symptoms can occur in a variety of mental
and substance abuse disorders. In particular, “neurovegetative” (poor sleep, sweating, loss of appetite, tremors,
high blood pressure), anxiety and depressive symptoms
are well established components of opioid and alcohol
dependence and withdrawal, which are currently being
treated with psychotropic drugs, including benzodiazepines, valproate and antiadrenergic agents [8, 15].
Xenon is a monatomic inert gas with very low chemical
reactivity. It is colorless, odorless and heavy. Xenon has
a very low blood-gas partition coefficient, rapidly penetrates the blood–brain barrier, which makes it an ideal
general anesthetic. Xenon is a competitive N-methyld-aspartate (NMDA) receptor antagonist, which it
exhibits through binding to glycine site of glutamatergic NMDA receptor [16]. In addition, xenon reduces
excitatory neurotransmission through downregulation
of 5-HT3 [17], nicotinic acetylcholine [18], potassium
channel [19], HCN channel [20], and AMPA [21]. It also
increases inhibitory neurotransmission by upregulating
TREK1 [22]. Of relevance to fear associated conditions
such as PD, the role of NMDA receptors in modulation
of fear memories has previously been suggested [23].
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Accordingly, Meloni et al. demonstrated that administration of xenon gas in a rat model of fear memory reconsolidation—a state in which recalled memories become
susceptible to modification, reduced conditioned fear
induced freezing [24].
Other psychiatric uses of xenon have been explored, for
example, promising results on the use of inhaled xenon in
opioid and alcohol withdrawal states, based on its pharmacokinetic effects have been reported [25–28]; in particular, its anti-stress properties, decreased sensitivity to
pain and improved adaptation [29, 30]. However, there is
paucity of research on the use of xenon outside of anesthesiology and addiction. According to some authors, its
therapeutic properties are likely based on its effect on the
glutamatergic system neuromodulation [31] via inhibition of NMDA receptors and reduction in binding of glutamate [31–33]. It was also shown that xenon at a dose of
30–50–70% in the gas mixture does not alter plasma concentrations of dopamine and norepinephrine, but causes
a significant reduction of the level of adrenaline and cortisol [34].
It should also be noted that due to the biochemical
inertness xenon, it exhibits no acute or chronic toxicity
[35], embryotoxic or teratogenic effects, it is non-allergenic [18, 33], and does not alter the integrity of brain
structures [36].
In recent studies it was demonstrated that the glutamatergic system plays a significant role in the regulation of anxiety. In particular, blockade of glutamatergic
transmission in the periaqueductal gray matter lead to
restoration of normal behavior in animals, and glutamate
antagonists exhibited anxiolytic properties in experimental conditions [37].
In addition, preclinical studies have shown that blocking the glycine site NMDA-glutamate receptors results
in anxiolytic effects [38]. Some supporting evidence that
implicates glutamate in the pathogenesis of anxiety disorders stems from the efficacy of pregabalin, in which
the mechanism of action is associated with inhibition of
glutamate release [39]. Thus, on the basis of clinical data
previously obtained from the use of xenon in anesthesiology and addiction medicine, as well as based on its
receptor activity profile (reduction of glutamatergic neurotransmission) it can be expected that xenon possesses
an independent anti-anxiety effect. The preliminary experience of using xenon in the outpatient treatment of various psychiatric and addictive diseases has been marked
by its clear anxiolytic effect, which triggered our desire to
study xenon’s effect on specific anxiety disorders. PD was
selected because of its paroxysmal, easily quantifiable
nature and a high degree of recurrence, and also because
the “panic attack” phenomenon occurs widely in other
anxiety states.
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The clinical study presented aimed to: (a) study efficacy
and adverse effect profile of xenon in acute treatment
as a monotherapy for “pure” PD; (b) assess efficacy and
adverse effect profile of xenon in treatment of PD in the
presence of other mental illness comorbidities; and (c)
quantify the duration of xenon’s therapeutic effect.

Methods
Patients

This investigator-initiated study was performed under
a prospective clinical trial protocol approved by the
Institute of Mental Health and Addictology, which is
accredited by the Ministry of Health of the Russian Federation to conduct clinical trials (#57689). Study conduct was in compliance with all ethical standards and
good clinical practice. All study participants provided
written informed consent prior to undergoing any protocol-related procedures. The study was registered at
http://www.isrctn.com (number in process, application
#32439). Ninety outpatients with a diagnosis of “panic
disorder” (F41.0) according to ICD-10 were enrolled
through the Institute of Mental Health and Addictology.
Five patients dropped out of the study due to minor side
effects, predominantly lightheadedness and headaches,
and 4 patients dropped out of the study for unspecified
reasons. As the intention to treat analysis was not utilized
due to the open label design of the study, 81 patients with
PD (49 women and 32 men), mean age was 35.2 years
(range 18–69) were studied. Patients were randomized
into 2 groups: with “pure” PD (group 1) and “comorbid”
PD, when it was co-diagnosed with other mental illnesses
(group 2). All patients with isolated PD (group 1, n = 42)
received monotherapy with xenon at the aforementioned schedule, while the majority of patients (94.9%)
with PD and comorbid conditions, which were predominantly depression (group 2, n = 39), in addition to xenon
administration continued treatment for comorbid psychiatric disorders, which mainly consisted of antidepressants (SSRIs and SNRIs). In these patients, the reason for
xenon treatment was the increase in the frequency and
severity of panic attacks despite ongoing treatment with
stable pharmacotherapy of at least 3–6 months’ duration.
Xenon administration

Administration of xenon was performed through inhalation of xenon–oxygen mixtures that were escalated from
15%/85% to 30%/70% with titration increments of 5% per
session. Each patient in the study underwent between 6
and 7 treatments with xenon–oxygen mixture. The first
three sessions were carried out daily and from session
4 onward—every other day. The selected dosing regime
and the composition of the gas mixtures were based on
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the historical evidence of safety of subanesthetic use of
xenon in imaging [40–42].
Medical grade xenon (“medksenon”®, 99.9999%, manufacturer: Atommedcenter, Moscow, Russia) and medical
grade oxygen in separate containers were admixed. Mixing and administration of gases in preset concentration
and volume was accomplished with the use of the medical device MAGi-AMTS1, which enables the operator to
adjust the concentration of xenon in the gas mixture, and
which contains the electronic flow meter with a software
module that allows for such adjustments. Administration of xenon–oxygen mixture to the patient was carried
out via a face mask. Patients were asked to slowly inhale,
holding breath for 5–10 s; exhale into the loop and after
35–40 s exhale outside the contour and breath in the new
portion of gas mixture. Xenon inhalation lasted from 2.5
to 4 min, and the xenon consumption was capped at 3.0 L
per procedure. The patients were assessed subjectively by
the provider, while the vital signs (pulse, blood pressure,
oxygen saturation) were continuously monitored.
Patient assessment

Patients were evaluated after each xenon inhalation and
at 30 and 180 days after completion of treatment. To this
end, we employed clinical psychopathological and clinical catamnestic methods, and psychometric scales that
are widely used internationally to assess the treatment
of mental disorders. Scale Assessment, Zung Self-Rating Anxiety Scale (SAS) was performed prior to starting therapy (V1), and at 1 and 6 months after treatment.
According to this scale, SAS index of less than 45 points
corresponds to the normal value, 45–59—to mild-tomoderate degree of anxiety, 60–74—to high degree of
anxiety, more than 75—to an extremely high-level of
anxiety. Hospital Anxiety and Depression Scale (Hospital Anxiety and Depression Scale, HADS_T-anxiety
subscale, HADS_D-Depression subscale) was used prior
to the (V1), after the third (V3) and sixth (V6) xenon
administrations. Categories for the assessment for each
of the following subscales are as follows: 0–7 points—
normal (absence of reliable pronounced symptoms of
anxiety/depression); 8–10 points—subclinical anxiety/
depression; 11 points and above—symptomatic anxiety/
depression. Clinical Global Impression Scale (CGI-I—
improvement subscale, CGI-S—severity of the disease
subscale) was used before treatment and after each of
the following 6 xenon treatments (V1, V2, V3, V4, V5,
V6).
Statistical analysis of the results was carried out via
statistical and analytical methods using Microsoft Excell
2000 program and with Statistica statistical tools (http://
www.statsoft.com/, http://www.statsoft.ru/).
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Results
The two groups of patients, with “pure” PD (group
1, n = 42) and with “comorbid” PD (group 2, n = 39)
were well matched (Table 1). For patients in group 2
the following comorbid disorders were most commonly
observed: mixed anxiety-depressive disorder (43.6%),
bipolar affective disorder (10.3%), recurrent depressive
disorder (10.3%), obsessive–compulsive disorder (5.1%),
and other nonpsychotic mental disorders (12.8%, heading
F48).
Changes in the subscale of “anxiety” in Hospital Anxiety and Depression Scale (HADS_T) are presented in
Fig. 1. The total score on this scale in both groups corresponded to the level of “clinically severe anxiety” (17.7
and 19.0, respectively), and showed a decrease (−4.6 and
5.7 points, respectively) after 3 sessions (V3) of xenon
administration (13.3 and 13.3, respectively). By the end
of treatment (V6), the overall scores in both groups corresponded to the category of the “norm” for HADS_T

Table 1 Social and demographic characteristics of the
patients
Group
“Pure”
PD (n = 42)

“Comorbid”
PD (n = 39)

Total (n = 81)

Age, years
Mean

36.1

Standard devia- 12.90
tion

34.3

35.2

12.20

12.52

Median

32.0

33.0

33.0

Minimum

19

18

18

Maximum

69

68

69

Male, n (%)

22 (52.4%)

10 (25.6%)

32 (39.5%)

Female, n (%)

20 (47.6%)

29 (74.4%)

49 (60.5%)

Sex

Employment
No, n (%)

19 (45.2%)

18 (46.2%)

37 (45.7%)

Yes, n (%)

23 (54.8%)

21 (53.8%)

44 (54.3%)

Disease duration, months
Mean

8.9

Standard devia- 5.28
tion

16.9

12.8

7.54

7.60

Median

6.0

18.0

12.0

Minimum

3

3

3

Maximum

18

24

24

Marriage status
No, n (%)

16 (38.1%)

21 (53.8%)

37 (45.7%)

Yes, n (%)

26 (61.9%)

18 (46.2%)

44 (54.3%)

Children
No, n (%)

17 (40.5%)

21 (53.8%)

38 (46.9%)

Yes, n (%)

25 (59.5%)

18 (46.2%)

43 (53.1%)

Fig. 1 Reduction in Anxiety Score on the HADS_T Scale after Xenon
Administration. Patients with only PD (group 1, n = 42) and “comorbid” PD (group 2, n = 39) where administered 6–7 sessions of xenon
inhalation as described in “Methods”. Analysis of HADS_T score was
performed. Error bars indicate 95% CI

Scale. Statistical analysis of the changes in SAS Scale
using paired test samples is presented in Table 2.
Analysis of Clinical Global Impression Scale Improvement Subscale (CGI-I) changes after the third treatment
shows a more significant improvement with xenon treatment (“marked improvement” on the CGI-I) in group
1 than in group 2 (40.5 and 10.3%, respectively, when
compared to baseline). This trend persisted after 6 treatments: the indicator “very much improved” in patients
with “pure” PD was 52.4%, while for those with “comorbid” PD it was only 12.8% (Table 3). According to the
Clinical Global Impression Scale Severity of the Disease
Subscale (CGI-S) (Table 4), before the start of treatment,
both groups of patients demonstrated a pronounced
degree of impairment: the indicator “significantly pronounced disease” was at 90.5 and 87.2%, respectively.
After the third procedure, reduction in the severity of
disorders was more pronounced in group 1: the indicator “moderately severe disease” was 48.7 and 11.9%,
respectively. At the same time, upon completion of xenon
treatments the differences between the two groups disappeared and most patients in both groups reached the
“borderline” level (82.1 and 88.1%, respectively).
Thus, by analyzing the changes in the indices of psychometric scales (HADS_T, CGI-I, CGI-S) it can be concluded that the use of xenon treatment in PD produced
rapid onset of action, statistically significant clinical
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Table 2 Results of statistical analysis of HADS_T assessments of changes from baseline (V1) using a paired t test for the
evaluation visits within each patient group
Paired differences
Mean

t

Std. deviation

Std. error mean

df

Sig. (2-tailed)

95% confidence interval
Lower

Upper

Group 1
HADS-T, V3 to HADS-T, V1
HADS-T, V6 to HADS-T, V1
Group 2
HADS-T, V3 to HADS-T, V1
HADS-T, V6 to HADS-T, V1

−4.595

3.379

.521

−11.214

3.440

.531

−5.692

1.749

.280

2.882

.461

−11.436

−5.648

−12.286
−6.259

−12.370

−8.813

41

.000

−10.142

−21.129

41

.000

−5.125

−20.319

38

.000

38

.000

−3.542

−10.502

−24.782

Table 3 Changes in CGI-I Scale during treatment
Group
“Pure” PD (n = 42)

“Comorbid” PD (n = 39)

Total (n = 81)

n

n

n

%

%

%

CGI-I, V2
Marked improvement

5

11.9

5

12.8

10

12.3

Minimal improvement

20

47.6

24

61.5

44

54.3

No changes

30.9

15

35.7

10

25.6

25

Minimal deterioration

1

2.4

0

.0

1

1.2

Marked deterioration

1

2.4

0

.0

1

1.2

42

100.0

39

100.0

81

100.0

Overall
CGI-I, V3
Marked improvement

17

40.5

4

10.3

21

25.9

Minimal improvement

23

54.8

27

69.2

50

61.7

No changes
Overall

2

4.8

8

20.5

10

12.3

42

100.0

39

100.0

81

100.0

CGI-I, V4
Marked improvement

34

81.0

10

25.6

44

54.3

Minimal improvement

8

19.0

25

64.1

33

40.7

No changes
Overall

0

.0

4

10.3

4

4.9

42

100.0

39

100.0

81

100.0

CGI-I, V5
Very marked improvement
Marked improvement
Minimal improvement
Overall

2

4.8

0

.0

2

2.5

40

95.2

24

61.5

64

79.0

0

.0

15

38.5

15

18.5

42

100.0

39

100.0

81

100.0

CGI-I, V6
Very marked improvement

22

52.4

5

12.8

27

33.3

Marked improvement

20

47.6

34

87.2

54

66.7

Overall

42

100.0

39

100.0

81

100.0

improvement, and complete cessation of panic attacks
after the 6th treatment.
Symptom changes on the SAS scale are presented
in Fig. 2. The initial presentation in both groups

corresponded to “high level of anxiety”(72.7 and 64.1,
respectively). One month after treatment, all patients
showed a decrease in the SAS total score, although it
was more pronounced in group 1: 36.5 points (which
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Table 4 Changes in CGI-S Scale during treatment
Group
“Pure ”PD (n = 42)

“Comorbid” PD (n = 39)

Total (n = 81)

n

n

n

%

%

%

CGI-S, V1
Moderately expressed disease

4

10.3

1

2.4

5

6.2

Significantly expressed disease

34

87.2

38

90.5

72

88.9

Serious disease
Total

1

2.6

3

7.1

4

4.9

39

100.0

42

100.0

81

100.0

CGI-S, V2
Moderately expressed disease

19

48.7

1

2.4

20

24.7

Significantly expressed disease

20

51.3

39

92.9

59

72.8

Serious disease
Total

0

.0

2

4.8

2

2.5

39

100.0

42

100.0

81

100.0

CGI-S, V3
Moderately expressed disease

19

48.7

5

11.9

24

29.6

Significantly expressed disease

20

51.3

37

88.1

57

70.4

Total

39

100.0

42

100.0

81

100.0

CGI-S, V4
Weakly expressed disease
Moderately expressed disease

0

.0

20

47.6

20

24.7

20

51.3

22

52.4

42

51.9

Significantly expressed disease

19

48.7

0

.0

19

23.5

Total

39

100.0

42

100.0

81

100.0

CGI-S, V5
Borderline state

0

.0

6

14.3

6

7.4

Weakly expressed disease

1

2.6

36

85.7

37

45.7

Moderately expressed disease

37

94.9

0

.0

37

45.7

Significantly expressed disease

1

2.6

0

.0

1

1.2

39

100.0

42

100.0

81

100.0

Total
CGI-S, V6
Normal state
Borderline state
Weakly expressed disease
Total

0

.0

5

11.9

5

6.2

32

82.1

37

88.1

69

85.2

7

17.9

0

.0

7

8.6

39

100.0

42

100.0

81

100.0

corresponds to “no anxiety”) against 46.8 points in group
2 (“minimum degree of anxiety”). Furthermore, these
parameters remained approximately at the same level
throughout the study follow up (34.5 and 47.9, respectively). Statistical analysis of changes in SAS scale using
paired test samples are presented in Table 5.
As noted above, in the modern classifications, in addition to “major” episodes that meet the criteria of a panic
attack based on the number of symptoms, “limited
symptom” (“minor”) panic attacks have been described,
which, nevertheless, have an impact on social functioning and quality of life. As seen in Fig. 3, the mean number
of “major” panic attacks per month in group 2 was even
greater than that of the group 1 (7.7 and 11.7, respectively),

while the number of “minor” attacks were slightly higher in
group 1, or patients with “pure” PD (44.8 and 41.7, respectively). 6 months after treatment “major” panic attacks
were absent in both groups, while “minor” panic attacks
occurred in a very few cases (.3–1, respectively).
The results of SAS scales and lack of panic attacks after
6 months of treatment indicate the sustained anxiolytic
effect of xenon administration.
As has already been noted, most often encountered
comorbid mental conditions in group 2 included depressive disorders. The high degree of severity of depressive
symptoms indicate that the traditional in these cases
antidepressant therapy was ineffective. While the effect
of xenon directly on depression is beyond the scope of
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the active phase of treatment “clinically severe depression” was negligible in patients of group 1 (2.4%), and it
decreased to 46.2% in group 2.
Xenon therapy was generally well tolerated, side effects,
mainly headache and dizziness, were rare and lead to
only 5 patients dropping out from the study (5.8%).
After carefully reviewing the data from these patients,
it should be noted that four of them were found to have
clinical symptoms of mild organic brain disease of vascular origin (F06.71 heading ICD-10), which is indirectly
confirmed by the results of head and neck Doppler ultrasound. It was previously demonstrated that inhalation of
xenon can increase cerebral blood flow [6].

Fig. 2 Reduction of the Zung Self-Rating Anxiety Scale (SAS) Score
Subsequent to Xenon Administration. Patients with only PD (group 1,
n = 42) and “comorbid” PD (group 2, n = 39) where administered 6–7
sessions of xenon inhalation as described in “Methods”. Analysis of
SAS score was performed. Error bars indicate 95% CI

this study, the analysis of HADS_T subscale “Depression”
of HADS_D scale (Table 6) warrants some observations
on this topic. According to HADS_D, “clinically severe
depression” was absent in 66.7% of the patients in group
1 before the start of treatment, while it was present in
92.3% of group 2. After 3 xenon treatments it was absent
in 90.5% of patients in group 1, but was still present in
the majority of patients in group 2 (82.1%). By the end of

Discussion
Despite the fact that SSRIs, SNRIs and benzodiazepines
have proven efficacy in the treatment of PD, the delayed
onset of action for the former and the side effects and the
risk of dependence for the latter limit its use in the most
active cohort of patients with PD. In addition, there are
currently insufficient data on the treatment of refractory
PD and on effective augmentation strategies, as well as
on the treatment PD with comorbid mental illnesses.
The inert gas xenon was first shown to possess anesthetic properties over 50 years ago [43]. Over the last
10 years the interest in xenon as an inhalational anesthetic has increased due to several characteristics
associated with its use: cardiovascular stability, rapid
induction and emergence from anesthesia, and its analgesic effects—all of which make it an ideal anesthetic
[44]. As a result, xenon has become more routinely used
as an anesthetic agent in Europe and Japan and has garnered increasing interest in the United States although,
primarily due to the higher cost of xenon as compared

Table 5 Descriptive statistics for the Zung Self-Rating Anxiety Scale (SAS) and changes compared with baseline (V1)
for the evaluation visits and patient groups
Paired differences
Mean

Std.
deviation

Std. error
mean

t

df

Sig.
(2-tailed)

95% confidence interval
of differences
Lower

Upper

Group 1
Pair 1
  Zung after 1 month, V1
Pair 2
  Zung after 6 months, V1
Group 2

−36.131

3.205

.495

−37.130

−35.132

−73.048

41

.000

−38.214

4.049

.625

−39.476

−36.952

−61.158

41

.000

−17.308

7.508

1.202

−19.742

−14.874

−14.395

38

.000

−16.154

7.562

1.211

−18.605

−13.702

−13.340

38

.000

Pair 1
  Zung after 1 month, V1
Pair 2
  Zung after 6 months, V1
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Table 6 Changes in the frequency of major and minor
panic attacks (per month)
Group
“Pure”
PD (n = 42)

“Comorbid”
PD (n = 39)

Total (n = 81)

The frequency of major panic attacks before treatment, times/month, V1
n

42

39

81

Mean

7.7

11.7

9.6

8.27

8.24

Standard devia- 7.85
tion
Percentile 25

1.0

4.0

2.0

Median

3.0

12.0

7.0

Percentile 75

16.0

16.0

16.0

Minimum

1

1

1

Maximum

24

28

28

The frequency of major panic attacks 6 months after treatment

Fig. 3 Changes in HADS D Scale (subscale “depression”) after Xenon
Administration. Patients with only PD (group 1, n = 42) and “comorbid” PD (group 2, n = 39) where administered 6–7 sessions of xenon
inhalation as described in “Methods”. Analysis of Analysis of HADS_T
score was performed. Error bars indicate 95% CI

to other inhalational anesthetics, it has not yet received
FDA approval. Evidence suggests that xenon’s biological
effects may be mediated through its ability to potently
block the NMDA receptors [45].
Furthermore, xenon has distinct advantages over other
NMDA antagonists, such as ketamine, for future translation to the clinical setting. First, subsedative concentrations of xenon that would sufficiently block the NMDA
receptor without producing anesthesia could potentially
be administered briefly in a safe and effective manner in
the outpatient setting with minimal medical monitoring.
Second, in contrast to existing NMDA receptor blockers
like ketamine, xenon has been shown to inhibit NMDA
receptor activity through competitive inhibition of the coagonist glycine at the glycine site of the NMDA receptor
[45]—a mechanism devoid of psychotomimetic effects.
On the basis of the result of this study’s clinical and
psychometric data with the use of scales assessing both
the severity of anxiety (SAS, HADS_T), and evaluation
of treatment effect in general (CGI-I, CGI-S), several preliminary conclusions can be made.
Firstly, when using xenon as an acute treatment of PD,
reduction in both frequency and severity of panic attacks
and anxiety level was observed during the first three treatment sessions, and by the end of treatment the vast number
of patients experienced complete resolution of panic attacks

n

42

39

81

Mean

.0

.0

.0

Standard devia- .0
tion

.0

.0

Percentile 25

.0

.0

.0

Median

.0

.0

.0

Percentile 75

.0

.0

.0

Minimum

0

0

0

Maximum

0

0

0

The frequency of minor panic attacks before treatment, times/month, V1
n

42

39

81

Mean

44.8

41.7

43.3

15.29

15.73

Standard devia- 16.18
tion
Percentile 25

28.0

28.0

28.0

Median

56.0

56.0

56.0

Percentile 75

56.0

56.0

56.0

Minimum

4

4

4

Maximum

84

56

84

The frequency of minor panic attacks 6 months after treatment, times/
month
n

42

Mean

.3

Standard devia- .46
tion

39

81

1.0

.6

2.64

1.89

Percentile 25

.0

.0

.0

Median

.0

.0

.0

Percentile 75

1.0

1.0

1.0

Minimum

0

0

0

Maximum

1

16

16

Changes minor panic attacks_V6_V1
n

42

39

81

Mean

−44.5

−40.7

−42.7

Standard devia- 16.19
tion

15.12

15.70

Percentile 25

−56.0

−56.0

−56.0
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Table 6 continued
Group
“Pure”
PD (n = 42)
Median
Percentile 75
Minimum
Maximum

−55.0

−28.0

−84.00

“Comorbid”
PD (n = 39)
−40.0

−27.0

−56.00

Total (n = 81)
−55.0

−28.0

−84.00

−4.00

−4.00

−4.00

n

42

39

81

Mean

−7.7

Changes_major panic attacks _V6_V1

Standard devia- 7.85
tion
Percentile 25
Median
Percentile 75
Minimum
Maximum

−16.0

−3.0

−1.0

−24.00

−1.00

−11.7

8.27

−16.0

−12.0

−4.0

−28.00

−1.00

−9.6

8.24

−16.0

−7.0

−2.0

−28.00

−1.00

while anxiety symptoms decreased to a subclinical level.
This conclusion is also true for patients with PD with comorbidities. Secondly, after treatment of both “pure” PD and PD
with psychiatric comorbidities, anxiolytic effect of xenon
was maintained for at least 6 months, which clinically manifested by cessation of panic attacks. Thirdly, treatment with
xenon was well tolerated, although it is possible that patients
with symptoms of cerebral insufficiency may experience
such adverse events as headache and dizziness. Fourthly,
although the effect of xenon on depressive disorders was
beyond the scope of this study, the analysis of the changes in
HADS_D scale allows us to make a preliminary conclusion:
in patients with PD and comorbid depressive symptoms
xenon treatment can not only lead to improvement in anxiety symptoms, but also to reduction of depression severity. In this sense, we see as highly relevant a conduct of the
study on the use of xenon as an adjuvant therapy for those
patients with depressive disorders and concomitant anxiety (with anxious distress according to DSM-5), which have
not sufficiently responded to treatment with conventional
pharmacotherapy. Fifthly, the current first line of treatment
of PD, in addition to pharmacotherapy, includes cognitivebehavioral therapy (CBT) [7]. At the same time, in clinical
practice, the use of CBT in patients with severe PD in the
early stages is often hampered by the high intensity of the
somatic symptoms of anxiety and hypochondriacal fears, for
relief of which providers often resort to the use of benzodiazepines. This approach can affect cognitive function and
impede effective personal involvement in psychotherapy.
In this sense, xenon treatment may be a good alternative to
benzodiazepine tranquilizers because of its good tolerability,
rapidity of onset and its lack of addictive potential.

The main methodological limitation of this study is
its open design. In order to determine the place xenon
in the treatment of PD additional randomized, placebocontrolled clinical trials of xenon and psychotropic substances used for the treatment of PD (SSRIs, SNRIs,
benzodiazepines) are needed. The design of such studies should distinguish between direct anxiolytic effect of
xenon and a potential placebo effect.

Conclusions
The present study is the first work on the use of xenon in
panic disorder that can give impetus to a more intensive
research into xenon’s place in the treatment of anxiety
and depressive disorders as both the adjunct and a potential alternative to the currently used psychotropic pharmacotherapy. Given the accepted use of subanesthetic
concentrations of xenon in imaging, and established
safety profile of concentrations similar to the ones utilized in the current study, future investigation of xenon
based therapeutics in prospective double blind placebo
controlled trials is warranted.
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